Ensysce Biosciences lost $82.3 million last quarter and finished buying Cy Biopharma while starting an important study.

ENSC · Ensysce Biosciences

The AI's read

The larger cash balance gives Ensysce more funds available, but the report does not say how long they will last. The quarterly loss exceeded that cash balance, though the report does not say how much of the loss used cash. Adding CY200 and completing study enrollment are signs of research progress. The report gives no study results, so the cash, loss, and research updates point in different directions.